Division of Merck & Co. Inc.
Latest From Merck BioVentures
Germany’s Merck is one of the multinationals said to be in negotiations with the South Korean firm Hanwha over the possible licensing of a biosimilar version of Amgen’s blockbuster rheumatoid arthritis treatment Enbrel and/or related technology.
Hanwha Biologics CEO Paul Coleman On Developing Biosimilars In Korea: An Interview With PharmAsia News (Part 1 of 2)
The former Biogen Idec exec sits down to talk about Hanwha’s biosimilars strategy and pipeline, and why its deal fell apart with Merck to develop a biosimilar of Enbrel.
Plus a look at Roche/Chiasma, Chiesi/Cornerstone, Eisai/Valeant and more
Developments in off-label enforcement and scrutiny of economic superiority claims, new approaches to R&D, and biosimilars are among issues that captured readers’ attention last year.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.